RADEK SKODA to Calreticulin
This is a "connection" page, showing publications RADEK SKODA has written about Calreticulin.
Connection Strength
1.232
-
Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms. Blood. 2014 Apr 24; 123(17):2744-5.
Score: 0.448
-
Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023 04 20; 141(16):1909-1921.
Score: 0.209
-
[Myeloproliferative neoplasms - Update on diagnosis and treatment]. Ther Umsch. 2019; 76(9):487-495.
Score: 0.155
-
Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency. Blood. 2016 06 23; 127(25):3253-9.
Score: 0.128
-
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014 Apr 03; 123(14):2220-8.
Score: 0.110
-
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera. Leukemia. 2025 May; 39(5):1135-1145.
Score: 0.060
-
Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis. Nat Commun. 2023 10 12; 14(1):6414.
Score: 0.054
-
Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. 2017 12 28; 130(26):2848-2859.
Score: 0.036
-
Angiogenic factors are increased in circulating granulocytes and CD34+ cells of myeloproliferative neoplasms. Mol Carcinog. 2017 02; 56(2):567-579.
Score: 0.033